Compare IDR & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDR | CYBN |
|---|---|---|
| Founded | 1996 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Precious Metals | Pharmaceuticals and Biotechnology |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 378.0M | 416.1M |
| IPO Year | N/A | N/A |
| Metric | IDR | CYBN |
|---|---|---|
| Price | $48.73 | $8.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $17.50 | ★ $74.50 |
| AVG Volume (30 Days) | 745.4K | ★ 916.5K |
| Earning Date | 11-12-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.70 | N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $35,424,313.00 | N/A |
| Revenue This Year | $55.62 | N/A |
| Revenue Next Year | $23.93 | N/A |
| P/E Ratio | $65.85 | ★ N/A |
| Revenue Growth | ★ 61.35 | N/A |
| 52 Week Low | $10.06 | $4.81 |
| 52 Week High | $54.70 | $10.73 |
| Indicator | IDR | CYBN |
|---|---|---|
| Relative Strength Index (RSI) | 62.33 | 68.97 |
| Support Level | $45.40 | $7.85 |
| Resistance Level | $49.26 | $9.12 |
| Average True Range (ATR) | 3.48 | 0.51 |
| MACD | 0.22 | 0.15 |
| Stochastic Oscillator | 78.66 | 68.59 |
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.